
When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.

Retirees don’t need the highest yield on the board. They need the check to keep arriving, and to keep growing, through every recession, rate cycle, and regime change. Three Dividend Kings fit that brief: Coca-Cola, Johnson & Johnson, and PepsiCo. Each has raised its payout for decades without a cut, and one benchmark says it […]

Some companies have raised their dividends through recessions, pandemics, wars, and market crashes without missing a single year, and five of them may be the steadiest income plays a retiree can own right now.

Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

A seven-figure portfolio looks like security until federal taxes, Medicare surcharges, Social Security phase-ins, and inflation each take their share. What actually clears into your checking account from $1.55 million depends on decisions most retirees never see coming.
Treasuries now yield nearly 5%, raising the stakes for every dividend stock in a boomer portfolio. Five companies have raised their payouts through recessions, inflation spikes, and rate cycles, and the case for owning them lifetime has never required more scrutiny.
Some companies have handed investors a bigger paycheck every single year for more than six decades, surviving every recession and rate shock along the way. Five of them look particularly compelling right now, and one trades at a price not seen in over a year.

These stocks can help you withstand (almost) any storm.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.
Wall Street is set to open higher on Thursday as strong Microsoft results helped technology stocks recover from their sharp post-Federal Reserve sell-off. Dow Jones futures were up 225 points, or 0.4%, while S&P 500 futures pointed to a 0.6% gain and the Nasdaq was called 1.3%...
July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.
July 29 (Reuters) - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed

<body><p>STORY: :: New York / July 27, 2026</p><p>:: Dietrich Knauth, Legal Reporter</p><p>"After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement. Why are they settling now? </p><p>:: Why did J&J settle after more than a decade of talc litigation?</p><p>"So tens of thousands of women have accused Johnson& Johnson of causing their ovarian cancer. They've alleged that talc-based products, including baby powder, have been contaminated with asbestos and caused them to develop cancer after using these products for a long period of time. Johnson& Johnson has denied that, but these cases have continued to go to trial."</p><p>"And after a couple of attempts to settle these cases through bankruptcy courts, Johnson& Johnson has now reached a deal where they think they can end all of these cases for an overall payment that is about $5.5 billion, although that number could rise depending on how many people participate in the settlement."</p><p>"One of the plaintiff's lawyers told me today that he thinks it's closer to $7 billion. That's not something we're going to know for some time."</p><p>:: Could J&J still face new talc lawsuits in the future?</p><p>:: Johnson & Johnson</p><p>"It does not fully close the door on all future talc litigations. Somebody could develop cancer in the future, decide that they want to file a lawsuit against Johnson& Johnson, because they think that company's product caused their cancer. The reason for that is that there's something called a latency period, which is essentially the delay between when you experience the factors that caused your cancer and when that cancer actually shows up."</p><p>"But, you know, this deal basically gets rid of all of the existing cases. That's the idea."</p><p>J&J reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs' lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court. </p><p>J&J won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer.</p><p>J&J has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.</p><p>Before the bankruptcy attempts, J&J had a mixed record in talc trials, with a multibillion verdict in favor of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.</p><p>Unlike the proposed bankruptcy settlements, Monday's agreement applies only to existing claims and does not address future lawsuits.</p></body>
The healthcare company said the agreement covers the remaining ovarian talc litigation in federal multidistrict litigation proceedings and related state court cases.
A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.
Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.
Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.
Seventy companies have raised their dividends through every recession and rate shock for at least a quarter century, but a bruising few quarters for some of NOBL's most-watched names put that unbroken record under real pressure heading into mid-2026.
A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.
The typical American household spent $78,535 in 2024. Headline PCE inflation was running at 4.1% year over year in May 2026, which means the same lifestyle can become thousands of dollars more expensive in a single year. Social Security benefits are rising 2.8% in 2026, but that adjustment may not fully offset the higher cost ... The Portfolio That Lets You Ignore Inflation
Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.
Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data. Nasdaq 100 futures added 0.4%. Dow Jones Industrial Average futures rose 81 points, or 0.2%.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.